Aprea Therapeutics, Inc. Stock Price, News & Analysis

Aprea Therapeutics (Nasdaq: APRE) announced that four abstracts have been accepted for poster presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain, from October 23-25, 2024. The posters showcase progress in Aprea's oncology pipeline of DNA damage response (DDR) inhibitors, featuring updates on two clinical-stage candidates: APR-1051 and ATRN-119.

The presentations include two clinical posters on the safety and efficacy of APR-1051 (a WEE1 inhibitor) and ATRN-119 (a novel macrocyclic ATR inhibitor) in patients with advanced cancers. Additionally, two preclinical posters will be presented, focusing on APR-1051's favorable characteristics for treating CCNE1-overexpressing cancers and the development of macrocyclic ATR inhibitors for cancer treatment.

Aprea Therapeutics (Nasdaq: APRE) has engaged Philippe Pultar, MD as senior medical advisor to support the development of APR-1051, their potential best-in-class WEE1 inhibitor. Dr. Pultar brings extensive oncology experience, including the development of azenosertib, another WEE1 inhibitor. This aligns with Aprea's commitment to providing top resources for their WEE1 inhibitor program.

The Phase 1 ACESOT-1051 study is ongoing, evaluating APR-1051 in advanced solid tumors with specific gene alterations. Aprea plans to update on this study by year-end 2024. The WEE1 program is part of Aprea's DDR-targeted therapeutics portfolio, aiming to deliver precision medicine solutions.

Dr. Pultar expressed excitement about APR-1051's potential, citing its differentiated profile and compelling pre-clinical data. Aprea's CEO, Oren Gilad, Ph.D., highlighted Dr. Pultar's expertise as valuable for advancing their WEE1 program. Concurrently, Dr. Nadeem Mirza will step down as Chief Medical Officer, effective October 9, 2024.

Halda Therapeutics, a biotech company developing RIPTAC™ (Regulated Induced Proximity TArgeting Chimeras) therapeutics for cancer, has appointed Christian Schade as President, CEO, and Board member. Schade brings over 20 years of pharma and biotech industry experience, including leadership in clinical pipeline development and value-creating deals. Tim Shannon continues as Board Chairman.

Schade's appointment comes as Halda prepares to enter clinical trials, with the first RIPTAC therapeutic expected to begin trials in the first half of 2025. The company is focusing on developing therapies for prostate and breast cancer. Schade's previous roles include CEO of Aprea Therapeutics, Growth Partner at Flagship Pioneering, and executive positions at Novira, Omthera Pharmaceuticals, and Medarex.

Aprea Therapeutics (Nasdaq: APRE), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, has announced its participation in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024. The event will be held virtually, featuring:

1. A webcasted presentation by Oren Gilad, Ph.D., President and CEO, at 12:30pm ET.

2. One-on-one meetings with investors throughout the event.

The webcast can be accessed via the conference home page or a direct link, and will be available for replay after the event. Investors interested in arranging meetings with management can contact Lytham Partners or register through the provided link.

Aprea Therapeutics (Nasdaq: APRE), a clinical stage biopharmaceutical company focusing on precision oncology through synthetic lethality, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024 in New York, NY.

Dr. Oren Gilad, President and CEO of Aprea, will deliver a corporate update during the conference. The presentation will be available on-demand starting at 7:00 A.M. (ET) on September 9, 2024, and will remain accessible for 90 days. Interested parties can access the webcast through the provided link.

Additionally, Aprea's management team will be available for one-on-one meetings with institutional investors during the conference. Attendees interested in scheduling a meeting are advised to contact their conference representative.

Aprea Therapeutics (Nasdaq: APRE), a clinical stage biopharmaceutical company focusing on precision oncology through synthetic lethality, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024 in New York, NY.

Dr. Oren Gilad, President and CEO of Aprea, will deliver a corporate update during the conference. The presentation will be available on-demand starting at 7:00 A.M. (ET) on September 9, 2024, and will remain accessible for 90 days. Interested parties can access the webcast through a provided link.

Additionally, Aprea's management team will be available for one-on-one meetings with institutional investors during the conference. Attendees interested in scheduling a meeting are advised to contact their conference representative.

Aprea Therapeutics (Nasdaq: APRE) reported Q2 2024 financial results and provided a business update. Key highlights include:

1. Enrollment began in the ACESOT-1051 Phase 1 trial for APR-1051, a WEE1 kinase inhibitor, with no myelosuppression observed in the first cohort.

2. Cash position of $28.7 million as of June 30, 2024, with runway extended into Q4 2025.

3. Q2 2024 operating loss of $3.8 million, compared to $3.7 million in Q2 2023.

4. Net loss of $3.5 million ($0.58 per basic share) for Q2 2024.

5. Ongoing progress in ABOYA-119 trial for ATRN-119, an ATR inhibitor.

6. Appointment of Nadeem Q. Mirza as Chief Medical Officer.

Aprea Therapeutics will host a virtual Key Opinion Leader (KOL) event on Monday, June 24, 2024, at 9:00 AM ET to discuss APR-1051, a highly selective, potentially best-in-class oral WEE1 inhibitor. The event will feature experts Joseph Vacca, PhD, and Eric J. Brown, PhD, who will delve into the drug's medicinal chemistry history, selective design, and preclinical findings.

APR-1051 targets WEE1, an enzyme important to the DNA damage response pathway, making it a validated oncology target. The drug is designed to minimize off-target toxicity and is currently being evaluated in the Phase 1 ACESOT-1051 trial for patients with significant unmet medical needs, including those with Cyclin E overexpression. The event will also include a live Q&A session.

Joseph Vacca, a seasoned medicinal chemist with significant contributions to several approved drugs, and Eric J. Brown, an expert on replication stress response, will lead the discussions. This event aims to provide a comprehensive overview of APR-1051 in the context of emerging WEE1 inhibitors while highlighting its potential benefits and ongoing research.

Aprea Therapeutics has announced the dosing of the first patient in the ACESOT-1051 Phase 1 trial for their oral WEE1 inhibitor, APR-1051. This study is evaluating APR-1051 as a monotherapy for patients with advanced solid tumors who have unmet medical needs. APR-1051, developed by Aprea, targets the WEE1 kinase, an enzyme involved in the DNA damage response pathway. The trial will assess safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy over 28-day cycles. The first part involves dose escalation, while the second part focuses on dose optimization. The trial aims to confirm APR-1051's safety and determine the recommended Phase 2 dose. Updates are expected by year-end 2024 with preliminary efficacy data in 2025.